Merck (MSD) has reported positive results from two Phase III clinical trials of its investigational 15-valent pneumococcal conjugate vaccine, V114.

V114 is an investigational 15-valent pneumococcal conjugate vaccine being developed to prevent pneumococcal disease in adults and children. The vaccine comprises pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein.

It includes 22F and 33F serotypes that are commonly related to invasive pneumococcal disease and not included in the pneumococcal conjugate vaccine currently licensed for adults.

The Phase III studies assess the safety, tolerability and immunogenicity of V114, and the vaccine candidate is said to have reached safety and immunogenicity objectives.

Data from the PNEU-WAY (V114-018) trial revealed that V114 induce an immune response to all 15 serotypes included in the vaccine, in adults aged 18 years or above with human immunodeficiency virus (HIV).

Meanwhile, the PNEU-FLU (V114-021) study results from healthy participants aged 50 years or older showed that V114 can be administered concomitantly with the quadrivalent influenza vaccine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Merck Research Laboratories vaccine clinical research executive director in biologics Dr Luwy Musey said: “Results from these first two Phase III studies of V114 are encouraging and we look forward to sharing additional data in the future from our ongoing clinical development programme, including our pivotal studies assessing the immunogenicity of V114 and its potential to protect against the serotypes most likely to cause invasive disease.”

The Phase III clinical development programme for V114 involves 16 studies assessing its safety, tolerability and immunogenicity in populations at increased risk for pneumococcal disease.

Merck plans to work with the US Food and Drug Administration (FDA) and other regulators to potentially file for licensure of the vaccine.

In May last year, the company reported positive results from the Phase II trial of V114.